Biovica takes the next step in the process of commercializing DiviTum by launching a subsidiary in the United States.
The subsidiary Biovica Inc is a sales company based in Delaware. The purpose of the US subsidiary is to establish DiviTum on the US market. DiviTum measures cell proliferation rate and the objective is to provide information regarding treatment efficacy faster than currently available methods. An extensive study program is ongoing in the US in collaboration with several universities and institutes. Biovica aims to enable a longer and better life for cancer patients, while at the same time optimize the resources used for cancer treatments.
”Local presence is important for getting closer to key customers and partners in the United States.” says Anders Rylander, CEO Biovica.
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.
Read more: www.biovica.com